vs
Side-by-side financial comparison of SES AI Corp (SES) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.6M, roughly 1.2× SES AI Corp). SES AI Corp runs the higher net margin — -373.5% vs -507.8%, a 134.3% gap on every dollar of revenue.
SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
SES vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.6M | $5.5M |
| Net Profit | $-17.0M | $-27.9M |
| Gross Margin | 11.3% | — |
| Operating Margin | -387.7% | -516.0% |
| Net Margin | -373.5% | -507.8% |
| Revenue YoY | — | 171.3% |
| Net Profit YoY | 50.7% | -48.3% |
| EPS (diluted) | $-0.05 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.6M | $5.5M | ||
| Q3 25 | $7.1M | $0 | ||
| Q2 25 | $3.5M | $2.0M | ||
| Q1 25 | $5.8M | $2.3M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | $-17.0M | $-27.9M | ||
| Q3 25 | $-20.9M | $-32.7M | ||
| Q2 25 | $-22.7M | $-26.9M | ||
| Q1 25 | $-12.4M | $-21.5M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | — | $-20.9M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | 11.3% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 73.7% | — | ||
| Q1 25 | 78.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -387.7% | -516.0% | ||
| Q3 25 | -262.0% | — | ||
| Q2 25 | -652.3% | -1347.1% | ||
| Q1 25 | -401.7% | -930.5% | ||
| Q4 24 | — | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | — | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | -373.5% | -507.8% | ||
| Q3 25 | -293.9% | — | ||
| Q2 25 | -642.2% | -1353.6% | ||
| Q1 25 | -214.6% | -935.2% | ||
| Q4 24 | — | -929.0% | ||
| Q3 24 | — | -1427.5% | ||
| Q2 24 | — | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | $-0.05 | $-0.08 | ||
| Q3 25 | $-0.06 | $-0.09 | ||
| Q2 25 | $-0.07 | $-0.09 | ||
| Q1 25 | $-0.04 | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.5M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $214.8M | $246.9M |
| Total Assets | $272.6M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.5M | $319.8M | ||
| Q3 25 | $35.3M | $297.3M | ||
| Q2 25 | $11.8M | $312.8M | ||
| Q1 25 | $56.1M | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $214.8M | $246.9M | ||
| Q3 25 | $228.2M | $219.0M | ||
| Q2 25 | $249.2M | $248.7M | ||
| Q1 25 | $269.9M | $55.1M | ||
| Q4 24 | — | $71.5M | ||
| Q3 24 | — | $88.8M | ||
| Q2 24 | — | $108.9M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | $272.6M | $343.3M | ||
| Q3 25 | $288.8M | $316.6M | ||
| Q2 25 | $290.5M | $333.3M | ||
| Q1 25 | $306.0M | $138.4M | ||
| Q4 24 | — | $160.4M | ||
| Q3 24 | — | $180.2M | ||
| Q2 24 | — | $200.4M | ||
| Q1 24 | — | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.4M | $-26.7M |
| Free Cash FlowOCF − Capex | $-11.1M | — |
| FCF MarginFCF / Revenue | -243.7% | — |
| Capex IntensityCapex / Revenue | 15.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-61.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.4M | $-26.7M | ||
| Q3 25 | $-14.3M | $-24.2M | ||
| Q2 25 | $-10.8M | $-20.2M | ||
| Q1 25 | $-22.8M | $-22.0M | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.5M | ||
| Q1 24 | — | $-19.8M |
| Q4 25 | $-11.1M | — | ||
| Q3 25 | $-14.7M | $-24.3M | ||
| Q2 25 | $-11.6M | — | ||
| Q1 25 | $-23.7M | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | -243.7% | — | ||
| Q3 25 | -206.9% | — | ||
| Q2 25 | -329.6% | — | ||
| Q1 25 | -410.0% | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 15.6% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
